IO Biotech expands collaboration with MSD – begins phase II trial
IO Biotech is initiating a third clinical collaboration with partner MSD to develop a combination treatment for three types of cancer, comprised of MSD's blockbuster drug Keytruda and IO Biotech's lead candidate. A phase II trial is on its way, and should it prove successful, IO Biotech will maintain global commercial rights.
by albert rønning-andersson, translated by daniel pedersen
Danish cancer company IO Biotech is entering its third clinical collaboration with US-based pharmaceutical giant MSD. The ambition is to develop a drug for the treatment of three different types of cancer, it reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
IO Biotech begins phase III trial with partner MSD
For subscribers
MSD Covid-19 treatment less effective than first thought
For subscribers
